207_Combined course Presentations

DAHANCA strategy: progression through clinical trials

DAHANCA Database Stage 3-4 Larynx and Pharynx

100

Standard 2007

83%

Benefit of Chemo- Radiotherapy

6 fx/wk + NIM + cis-P

645 pts

80

62%

6 fx/wk + NIM

Benefit of Accelerated Fractionation

60

713 pts

5 fx/wk + NIM 44%

411 pts

40

Benefit of Hypoxic Modification

27%

5 fx/wk

255 pts

20

Loco-regional control (%)

Standard 1985

0

0 6 12 18 24 30 36 42 48 54 60

Time after treatment (months)

Adapted from Overgard and Lassen 2015